Actualizado 20/05/2010 22:18
- Comunicado -

Phase III Study Showed First-Line Maintenance use of MabThera Doubles Likelihood of People With Follicular Lymphoma Livi

    
    All trademarks used or mentioned in this release are protected by law.
    Additional information
    - Roche in Oncology:
      http://www.roche.com/pages/downloads/com...
    - Cancer: http://www.health-kiosk.ch/start_krebs.htm
    - World Health Organization: http://www.who.int
    - Groupe d'Etude des Lymphomes de l'Adulte (GELA): http://www.gela.org

References:

[i] http://www.cancerbackup.org.uk/Cancertype/Lymphomanon-Hodgki...

[ii] http://www.lymphomacoalition.org

Roche Group Media Relations, Phone: +41-61-688-8888, e-mail: basel.mediaoffice@roche.com, Alexander Klauser, Martina Rupp, Claudia Schmitt, Nina Schwab-Hautzinger

Contenido patrocinado